Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||malignant glioma||not applicable||Bevacizumab + MEDI3617||Phase I||Actionable||In a Phase I trial, MEDI3617 in combination with Avastin (bevacizumab) resulted in no objective response (0/11) and stable disease in 18% (2/11) of patients with recurrent malignant glioma, with a median progression-free survival of 1.4 months (PMID: 29559563; NCT01248949).||29559563|